Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Marie_Noir
    Junior Member
    • Jul 2011
    • 8

    #1

    Variants outside genes

    Dear all,

    not sure if this is the best fitting place for my question, but since it arose during bioinformatic analysis of my NGS data, I will post it here.

    I realized that although I have data from EXOME sequencing (enrichment with a standard kit from, I have to look it up, either Agilent or Nimblegen), I encountered lots of variants OUT OF known genes (as mapped onto NCBI genes, build 37). I know, that enrichtment is not 100% perfect, but I want to know what percentage of "extragenic" enrichtment is "normal"? I would be happy to hear about your experiences.

    Thanks in advance!
  • swbarnes2
    Senior Member
    • May 2008
    • 910

    #2
    Originally posted by Marie_Noir View Post
    Dear all,

    not sure if this is the best fitting place for my question, but since it arose during bioinformatic analysis of my NGS data, I will post it here.

    I realized that although I have data from EXOME sequencing (enrichment with a standard kit from, I have to look it up, either Agilent or Nimblegen), I encountered lots of variants OUT OF known genes (as mapped onto NCBI genes, build 37). I know, that enrichtment is not 100% perfect, but I want to know what percentage of "extragenic" enrichtment is "normal"? I would be happy to hear about your experiences.

    Thanks in advance!
    The companies making the kits usually promise about 60% on target. Once I got 70%. So yeah, expect a lot of off target reads.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 08-11-2026, 10:35 AM
    0 responses
    11 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-06-2026, 07:41 AM
    0 responses
    30 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-03-2026, 10:13 AM
    0 responses
    48 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    48 views
    0 reactions
    Last Post SEQadmin2  
    Working...